Fusidic Acid
drugOn this page
Also known as Acide fusidiqueAcido fusidicoAnhydrous fusidic acidCEM-102Fucidin cavijectFucithalmicFusidateNSC-56192RamycinSQ 16,603SQ-16603TakstaACIDE_FUSIDIQUEC0088555Fucidin LEOFusidic acid
Summary
Fusidic Acid (CHEMBL374975) is an approved small-molecule protein synthesis inhibitor (ATC J01XC01); indicated across 6 conditions including bacterial infectious disease and eye infectious disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J01XC01 (+3 more)
- Indications: 6 conditions
- Clinical trials: 9
- Chemistry: 516.7 Da · C31H48O6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL374975 |
| Name | Fusidic Acid |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 3000226 |
| ChEBI | CHEBI:29013 |
| ATC | J01XC01, S01AA13, D06AX01, D09AA02 |
| Molecular formula | C31H48O6 |
| Molecular weight | 516.7 |
| InChIKey | IECPWNUMDGFDKC-MZJAQBGESA-N |
SMILES: C[C@H]1[C@@H]2CC[C@]3([C@H]([C@]2(CC[C@H]1O)C)[C@@H](C[C@@H]\4[C@@]3(C[C@@H](/C4=C(/CCC=C(C)C)\C(=O)O)OC(=O)C)C)O)C
IUPAC name: (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid
ChEBI definition: A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.
Pharmacological roles (ChEBI): protein synthesis inhibitor, EC 2.7.1.33 (pantothenate kinase) inhibitor.
Other ChEBI roles (chemical / environmental): Escherichia coli metabolite.
Also known as: Acide fusidique, Acido fusidico, Anhydrous fusidic acid, CEM-102, Fucidin caviject, Fucithalmic, Fusidate, Fusidic acid, NSC-56192, Ramycin, SQ 16,603, SQ-16603
Parent form; salt/anhydrous children: CHEMBL1256987
Patent coverage: 13,482 distinct patent families (47,850 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Bile salt export pump, ATP-binding cassette sub-family C member 2, Albumin, Broad substrate specificity ATP-binding cassette transporter ABCG2, Bile salt export pump.
Bioactivity
ChEMBL activities: 5 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| O70127 | 5.66 | Ki | 2200 | nM | CHEMBL_ACT_11002748 |
| Q63120 | 5.26 | Ki | 5500 | nM | CHEMBL_ACT_11003173 |
| Q63120 | 5.12 | Ki | 7600 | nM | CHEMBL_ACT_11003248 |
| ABCB11 | 5 | IC50 | 10100 | nM | CHEMBL_ACT_18051762 |
| ABCB11 | 5 | IC50 | 10100 | nM | CHEMBL_ACT_18129084 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| bacterial infectious disease | 4 | MONDO:0005113 | EFO:0000771 |
| eye infectious disorder | 4 | MONDO:0043885 | EFO:1001888 |
| keloid | 3 | MONDO:0005348 | EFO:0004212 |
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| skin disorder | 2 | MONDO:0005093 | EFO:0000701 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 9.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| Not specified | 3 |
| PHASE2 | 2 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03105505 | PHASE4 | UNKNOWN | The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis |
| NCT06695143 | PHASE3 | NOT_YET_RECRUITING | Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia |
| NCT06911424 | PHASE3 | RECRUITING | Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis |
| NCT01113125 | PHASE3 | UNKNOWN | Scars After Central Venous Catheters |
| NCT00948142 | PHASE2 | COMPLETED | Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections |
| NCT01756924 | PHASE2 | TERMINATED | Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection |
| NCT01153828 | Not specified | COMPLETED | EU PV for Retapamulin-Prescribing |
| NCT03052348 | Not specified | UNKNOWN | Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Active Comparator in Atopic Dermatitis. |
| NCT03173053 | Not specified | TERMINATED | S. Aureus Decolonization in HPN Patients. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).